Abstract
Background and Aims Cystic fibrosis (CF) is a multi-system genetic disorder affecting >72,000 people worldwide. Most people with CF experience gastrointestinal symptoms and some will develop complications such as distal intestinal obstruction syndrome. However the mechanisms of symptoms and complications are not understood. We evaluated gut function and transit of CF using magnetic resonance imaging (MRI). Our hypotheses were: oro-caecal transit time (OCTT) is longer in CF, with lower small bowel water content (SBWC).
Methods Twelve people with CF at a tertiary centre and 12 age and sex-matched controls underwent serial MRIs over 1 day, with meals at set times. The primary endpoint was OCTT, assessed by the appearance of a food bolus in the caecum. Other measures included SBWC, colonic volume, gastric half-emptying time and gastrointestinal symptoms.
Results OCTT was longer in CF (controls 210 minutes [173, 315] vs. CF 330 minutes [270, >360], p=0.04). There was no difference in gastric half-emptying times (controls 80 minutes [66, 88] vs. CF 97 [71, 128], p=0.3). Corrected SBWC was higher in CF (controls 34 L.min/m2 [28, 41] vs. CF 63 L.min/m2 [36, 80], p=0.021), with minimal second post-prandial decrease suggesting impaired ileal emptying. Corrected colonic volumes were higher in CF (controls 123 L.min/m2 [89, 146] vs. CF 186 L.min/m2 [166, 209], p=0.012). There were no differences in gastrointestinal symptoms.
Conclusions Significant differences in gut function and transit exist between CF and controls. Our methodology provides a platform for studying gastrointestinal function in CF and has identified new potential mechanisms of dysfunction.
Competing Interest Statement
CN and GM report grants and speaker honorarium from Vertex, outside the submitted work. APP reports grants from Thrasher Research Fund, grants from Action for A-T, grants from Health Education East Midlands, outside the submitted work; these grants are for the development of lung MRI in children and infants. RS reports grants from Zespri International Ltd and Sanofi-Aventis, as well as lecturing fees from Menarini and Alfawasserman, outside the submitted work. ARS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Novartis and personal fees from Vertex, outside the submitted work. In addition, ARS has a patent issued ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF.
Clinical Trial
ClinicalTrials.gov NCT03566550
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03566550
Funding Statement
This study was funded by the UK Cystic Fibrosis Trust, US Cystic Fibrosis Foundation, and NIHR Nottingham Biomedical Research Centre.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Grant support Cystic Fibrosis Trust
Cystic Fibrosis Foundation
NIHR Nottingham Biomedical Research Centre
Disclosures NSD, CLD, LM, LB, HLB, AJ, PG have nothing to disclose.
CN and GM report grants and speaker honorarium from Vertex, outside the submitted work.
APP reports grants from Thrasher Research Fund, grants from Action for A-T, grants from Health Education East Midlands, outside the submitted work; these grants are for the development of lung MRI in children and infants.
RS reports grants from Zespri International Ltd and Sanofi-Aventis, as well as lecturing fees from Menarini and Alfawasserman, outside the submitted work.
ARS reports grants from Vertex, as well as speaker honoraria and expenses from Teva and Novartis and personal fees from Vertex, outside the submitted work. In addition, ARS has a patent issued ALKYL QUINOLONES AS BIOMARKERS OF PSEUDOMONAS AERUGINOSA INFECTION AND USES THEREOF.
Data Availability
The original dataset will be made available by the corresponding author on request and after signing a confidentiality agreement not to publicly share the data.
Abbreviations
- (AUC)
- Area under the curve
- (CF)
- Cystic fibrosis
- (CFTR)
- Cystic fibrosis transmembrane conductance regulator
- (GLP-1)
- Glucagon-like peptide-1
- (MRI)
- Magnetic resonance imaging
- (OCTT)
- Oro-caecal transit time
- (PAC-SYM)
- Patient Assessment of Constipation-Symptoms
- (PAGI-SYM)
- Patient Assessment of Gastrointestinal Disorders Symptom Severity Index
- (QoL)
- Quality of life
- (SBWC)
- Small bowel water content
